Capricor Therapeutics
CAPR
37 hedge funds and large institutions have $19.9M invested in Capricor Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 3 closing their positions.
199% more call options, than puts
Call options by funds: $1.36M | Put options by funds: $455K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
9% more funds holding
Funds holding: 34 → 37 (+3)
5% more capital invested
Capital invested by funds: $18.9M → $19.9M (+$952K)
8.27% less ownership
Funds ownership: 21.48% → 13.21% (-8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$2.96M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$360K |
| 3 |
Renaissance Technologies
New York
|
+$338K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$172K |
| 5 |
Morgan Stanley
New York
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$9.54M |
| 2 |
Citigroup
New York
|
-$123K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$111K |
| 4 |
Millennium Management
New York
|
-$77.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$67.9K |
CAPR Hedge Fund Activity: Q4 2023 in Review
37 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2023, worth a combined $19.9M — up 5% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CAPR positions and 3 closed out — a net gain of 3 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $2.96M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $9.54M sold.
- 37 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2023, up from 34 in Q3 2023.
- Funds reported $19.9M of Capricor Therapeutics stock for Q4 2023, up 5% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest Capricor Therapeutics buyer in Q4 2023 was Woodline Partners, an estimated $2.96M added.
- The largest Capricor Therapeutics seller in Q4 2023 was Highbridge Capital Management, an estimated $9.54M sold.
Based on aggregated 13F filings for Q4 2023.